COVID-19 Vaccine and Infertility Treatment Outcomes



A retrospective age-matched cohort study was conducted to assess the influence of the COVID-19 mRNA vaccine on ovarian response and in vitro fertilization (IVF) treatment outcomes.


A total of 200 patients met the inclusion criteria and were matched to 200 control patients of similar age that were not vaccinated or previously infected with COVID-19. The groups had similar treatment protocols and ovulation-triggering and fertilization methods. Patients in the study and control groups had similar cycle characteristics in terms of total GT use, days of stimulation, maximal E2 levels, and endometrial thickness on the day of ovulation triggering. The mean number of oocytes retrieved per cycle and the maturation rate in intracytoplasmic sperm injection cycles were similar between groups. A total of 113 patients underwent freeze-all cycles due to fertility preservation, need for genetic analysis, surrogacy, or ovarian hyperstimulation.


The study group underwent oocyte retrieval 14–68 days after receiving COVID-19 vaccination. No difference was found in the mean number of oocytes retrieved per cycle between vaccinated and unvaccinated patients. Among 128 vaccinated and 133 unvaccinated patients who underwent fresh embryos transfers, no difference was demonstrated in the clinical pregnancy rates (32.8% vs. 33.1%), with 42 and 44 clinical pregnancies, respectively. The fertilization rates and mean number of cryopreserved embryos were similar between the 2 groups in freeze-all cycles. Among vaccinated and unvaccinated patients who underwent fresh embryo transfers, no difference was noted in the fertilization rate (64.81% vs. 61.98%) and transferred embryos’ quality. Regression models applied demonstrated no effect of the vaccine on oocyte yields and pregnancy rates.


Thus, it can be concluded that the COVID-19 mRNA vaccine does not affect the ovarian response or pregnancy rates in IVF treatment. Women should be vaccinated for COVID-19 before attempting to conceive via IVF treatments, given the higher risk of severe illness in pregnant women.

 

All About COVID-19 For Your Patients

WhiteCoats Insights For Your Practice



Join Thousands of Doctors who Trust WhiteCoats as their Professional Success Partner


For more queries, Call +91-7406-485-000 or mail us at sales@whitecoats.com


Download our App